Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Incyte Corporation's Stock Surge: Incyte shares rose 9.6% to $74.25 in pre-market trading following a collaboration announcement with QIAGEN to develop companion diagnostics for mutant CALR-expressing Myeloproliferative Neoplasms.
Pre-Market Trading Highlights: Several stocks experienced significant movements, including TMD Energy Limited (+203%), Regencell Bioscience Holdings (+169.6%), and Sarepta Therapeutics (-31.4%) after halting shipments and trials due to safety concerns.
Trade with 70% Backtested Accuracy
Analyst Views on TMDE
About TMDE
About the author

- Mixed Market Performance: U.S. stocks exhibited mixed performance amid the ongoing Iran-U.S. conflict, with the Dow Jones index falling 0.1% to 48,929.19 while the NASDAQ gained 0.37% to 22,751.80, indicating a complex market sentiment.
- Energy Sector Gains: Energy shares rose by 1.8% on Monday, reflecting optimistic expectations for energy demand despite the overall mixed market performance, suggesting strong investor confidence in the energy sector.
- Sealed Air Earnings Beat: Sealed Air Corp (NYSE:SEE) reported fourth-quarter earnings of 77 cents per share, exceeding analyst expectations of 73 cents, with quarterly sales reaching $1.401 billion, surpassing the forecast of $1.342 billion, demonstrating the company's robust profitability.
- International Market Fluctuations: European markets declined broadly, with the STOXX 600 falling 1.65%, reflecting global economic uncertainties, while Asian markets mostly closed lower, indicating investor concerns about future economic prospects.
- Market Performance: U.S. stocks opened lower this morning, with the Dow Jones index falling approximately 150 points, or 0.31%, to 48,826.07, indicating cautious market sentiment in response to economic data.
- Sector Dynamics: Despite the overall market decline, energy shares rose by 1.8%, reflecting investor optimism regarding energy demand, which could drive future profitability for related companies.
- Manufacturing Data: The ISM manufacturing PMI fell to 52.4 in February from 52.6 in the previous month, although this decline was above market expectations of 51.8, suggesting that manufacturing activity remains relatively stable and could positively impact economic recovery.
- International Market Impact: European markets were generally lower, with the STOXX 600 index dropping 1.7%, indicating a global market reaction to U.S. economic data that may influence investor risk appetite.
- Significant Revenue Growth: AMTD Digital Inc reported a staggering 565.7% year-over-year increase in FY25 revenue, reaching $136.1 million, which significantly enhances the company's financial performance and indicates strong market demand for its services.
- Stock Price Surge: Following the positive earnings report, AMTD Digital's shares jumped 24.4% to $2.18 in pre-market trading, reflecting investor optimism regarding the company's future growth potential and profitability.
- Positive Market Reaction: The robust financial results have garnered widespread attention in the market, potentially attracting more investors and further driving up the stock price while bolstering overall market confidence in the company.
- Strategic Implications: The revenue growth not only strengthens AMTD Digital's market position but also provides financial resources for future expansion and investments, enhancing its competitiveness in the digital finance sector.
- FDA Approval: The U.S. Food and Drug Administration (FDA) lifted the clinical hold on GH Research Plc's (NASDAQ:GHRS) Investigational New Drug Application (IND) on Monday, enabling the company to proceed with its clinical trials, which is expected to accelerate product development and enhance market competitiveness.
- Positive Market Reaction: Following the announcement, GH Research's stock surged 34.5% to $17.80, reflecting investor optimism about the company's future potential and likely attracting more investor interest in its subsequent developments.
- Industry Impact: This FDA approval not only brings direct capital inflow to GH Research but may also encourage other biotech firms to expedite their clinical trial processes, thereby fostering innovation and growth across the industry.
- Increased Investor Confidence: With the clinical hold lifted, GH Research is poised to accelerate its product launch timeline in the coming months, further boosting investor confidence and enhancing the company's market position in the biopharmaceutical sector.

Nektar Therapeutics Stock Surge: Shares of Nektar Therapeutics rose 30.3% in pre-market trading after announcing the release date for top-line data from its Phase 2b REZOLVE-AD clinical trial on June 24, 2025.
Market Movements: Several stocks experienced significant pre-market movements, with iBio, Inc. gaining 55.8% and Upexi, Inc. dropping 62.3%, reflecting a mix of gains and losses across various companies.

Sequans Communications Investment: Shares of Sequans Communications rose 42.2% in pre-market trading after announcing a $384 million strategic investment for a bitcoin treasury initiative.
Market Movements: Several stocks experienced significant changes in pre-market trading, with OceanPal Inc. surging 86.1% and COMPASS Pathways PLC dropping 30.8%.





